Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

NCT ID: NCT01175733

Last Updated: 2017-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-08
• Study Completion Date: 2016-05-31

Brief Summary

The purpose of this study is to investigate whether the addition of panitumumab to radiotherapy plus gemcitabine will increase the number of patients who are alive and progression free at 7 months.

Detailed Description

This is a phase I/II, multi-center dose escalation study.

Phase I:

Patients will be enrolled in cohorts of 3 per dose level until the MTD of panitumumab has been established.

Phase II:

Up to approximately 56 patients will be treated at the MTD level of panitumumab as established in the phase I part of the study.

Based on the historic data of patients with pancreatic cancer treated with gemcitabine based chemoradiation, we aim to increase the number of patients who are alive and progression free at 7 months from the historical value of 50% to 70% with the combination treatment of chemoradiation plus panitumumab.

Conditions

Pancreatic Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Panitumumab

Group Type: EXPERIMENTAL

Panitumumab

Intervention Type: DRUG

During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.

Interventions

Panitumumab

During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histological or cytological confirmed pancreatic cancer.
• Not eligible for curative resection.
• No distant metastases present.
• Previously untreated with chemotherapy and anti-cancer biologicals for current malignancy.
• No other current malignant disease, except for basal cell carcinoma of the skin.
• Measurable or evaluable disease as defined by RECIST 1.1 criteria.
• Performance status 0-2 Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Scale.
• Age ≥ 18 years.
• Adequate haematological and biological functions:

• Bone marrow function:

1. Neutrophils ≥ 1.5 x 109/L

2. Platelets ≥ 100 x 109/L

3. Hb ≥ 6 mmol/L

• Hepatic function:

1. AST/ALT and alkaline phosphatase (ALP) ≤ 2.5 x institutional upper limit of normal (ULN)

2. Bilirubin ≤ 1.5 times institutional ULN

• Renal function:

eGFR >50ml/min

• Metabolic Function:

1. Magnesium ≥ lower limit of normal

2. Calcium ≥ lower limit of normal.

• No imminent bowel obstruction.
• No active bleeding.
• No uncontrolled infection.
• Patients with reproductive potential must use effective contraception. Female patients must have a negative pregnancy test.
• Signed informed consent.

Exclusion Criteria

• Participation in another therapeutic clinical study within 30 days of enrollment or during this clinical study.
• No adequate radiation therapy possible: based on the opinion of the radiation oncologist when radiation therapy cannot be performed because radiation field is too large (PTV volume too large or OAR too high)
• History of allergic reactions to gemcitabine or antibody treatment.
• Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection, uncontrolled hypertension).
• Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 1 year before enrolment/randomization
• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
• Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance.
• Pregnant or breastfeeding women.
• Absence of adequate contraception for both male and female fertile patients for the duration of the study; and also for six months after last treatment.
• Known positive status for HIV and/or hepatitis B or C.
• Any reason why, in the investigator's opinion, the patient should not participate in the study.
• Drug or alcohol abuse.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: collaborator

Amsterdam UMC, location VUmc

OTHER

Sponsor Role: lead

Responsible Party

H.M.W. Verheul

Prof. Dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Henk MW Verheul, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam UMC, location VUmc

Locations

VU University Medical Center

Amsterdam, , Netherlands

Countries

Netherlands

Other Identifiers

20080686

Identifier Type: -

Identifier Source: org_study_id